ORELOX ORELOX BENDOXIM BENDOXIM PRELOX PRELOX POSOXIME ULTRADOXIM ULTRADOXIM BUTICEF BUTICEF CEFPOMED CEFPOMED VANTIN VANTIN NEUDOXINE NEUDOXINE NEUDOXINE CEDOXOWIN VOLVEZ NEFDOXIM NEFDOXIM EVODOXIM EVODOXIM CEFODEX CEFPO CEFPO CEFPO CURIDOXIME SUPRALOX SUPRALOX CEFPROX CEFPROX CEFPORITE CEFPORITE CEFPORITE ORIBRO ORIBRO ORIBRO CEFIDOX CEFIDOX QINK QINK QINK QINK WODOXIM WODOXIM SEFPOTIL CEFPOTIL EXPODOX EXPODOX EPODOX EPODOX CEFODEM CEF-POO MEGADOXIME POXIT R-ME GEFGLIT GEFGLIT TRUSEF C-DOXIME C-DOXIME DOXICEF DOXICEF DOX-B SHIME CEPOXIL APODOX APODOX PODICEF PODICEF OREMAS OREMAS CINOTEC BREEN BREEN ORETOX IPOD IPOD LEFODOX SYDOX CEFPODOXIME CEFPODOXIME MEDIDOXIME MEDIDOXIME PRAYDOX PODOX RTI-CEF RTI-CEF

Dose: 100 to 200 mg
Single Dose: 150 (150)
Frequency: 12 hourly
Route: PO
Instructions: Dose vary according to indication

Dose: 4 mg/kg
Single Dose: 4 (4)
Frequency: 12 hourly
Route: Oral
Instructions:

Cefpodoxime (Proxetil) is the derivative of Cefpodoxime. It is of Semi Synthetic origin and belongs to Cephem Carboxylic Acid. It belongs to Peptidoglycan synthesis inhibitor pharmacological group on the basis of mechanism of action and also classified in Antibiotic, Cephalosporin-3rd Gen pharmacological group.The Molecular Weight of Cefpodoxime is 557.60. Its pKa is 3.2.

Cefpodoxime is contraindicated in conditions like Hypersensitivity.

The severe or irreversible adverse effects of Cefpodoxime, which give rise to further complications include Thrombocytopenia, Hemolytic anemia, Hemolytic anemia, Stevens johnson syndrome, Stevens johnson syndrome, Eosinophilia, Eosinophilia, Hemolytic anemia, Anaphylactic shock, Acute liver injury, Purpuric nephritis, anaphylactic shock.Cefpodoxime produces potentially life-threatening effects which include Pseudomembranous colitis, Intravascular coagulation. which are responsible for the discontinuation of Cefpodoxime therapy.The signs and symptoms that are produced after the acute overdosage of Cefpodoxime include Diarrhea, Nausea & vomiting, Epigastric distress.The symptomatic adverse reactions produced by Cefpodoxime are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Fatigue, Vomiting, Anorexia, Diarrhea, Dyspnea, Chills, Urticaria, Glossitis, dizziness.

Cefpodoxime is primarily indicated in conditions like Benign gastric, duodenal or NSAID-associated ulceration, Gonorrhoea, Gynecological infections, Local infiltration, Lower respiratory tract infections, Otitis media, Sinusitis, Skin and soft tissue infections, Soft tissue and skin infections, Uncomplicated UTIs, Upper respiratory tract infections, Urinary tract infection.

No data regarding the interactions of Cefpodoxime was found.

Drug should not be given to Paediatrics, Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Inj (reconstituted soln) Store in refrigerator. Use within 14 days if kept at room temperature. Tab, Susp Store in a well closed container, at room temperature.

Cefpodoxime should be used with caution in patients with impaired kidney or liver function. Appropriate measure should be taken if secondary infection occurs. It should be used with caution (if contains tartrazine) in patients with aspirin hypersensitivity, because it may cause allergic reactions (including bronchial asthma).